SAB Biotherapeutics Inc Ordinary Shares SABS 深 沪
已收盘 05-15 16:00:00 美东时间
3.70
-0.190
-4.88%
华盛通- 最 高3.88
- 今 开3.84
- 成交量 94.46万股
- 最 低 3.59
- 昨 收 3.89
- 总市值 2.60亿
- 52周最高 6.60
- 市盈率 静 --
- 换手率 1.34%
- 52周最低 1.60
- 委 比 33.93%
- 总股本 7027.57万
- 历史最高 129.00
- 量 比 0.43
- 振 幅 7.46%
- 历史最低 1.00
- 每 手 1
- 风险率 0.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call
SAB Biotherapeutics (NASDAQ:SABS) reported first-quarter financial results on T...
05-12 20:59
SAB Biotherapeutics Q1 EPS $(0.35) Misses $(0.20) Estimate.
SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.20) by 75 percent. This is a 37.5 percent increase over losses of $(0.56) per share from
05-12 19:48
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Rodman & Renshaw Reiterates Buy on SAB Biotherapeutics, Maintains $13 Price Target
Rodman & Renshaw analyst Seema Sheoran reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $13 price target.
05-11 17:35
Emergent BioSolutions Signs Multi-Year, ~$50M Agreement With SAB Biotherapeutics For Development And Manufacturing Of SAB-142, SAB's Lead Program In Clinical Development For Autoimmune Type 1 Diabetes
The executed agreement is valued at approximately $50 million, of which $36 million is contingent on future regulatory approval and downstream milestones.Under the terms of the agreement, Emergent will provide end-to-end
04-29 19:38
SAB Biotherapeutics To Present Oral Presentation, Multiple Poster Presentations At 21st Immunology of Diabetes Society Congress On Its SAB-142 Program
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced
04-15 20:02
SAB Biotherapeutics Launches Public Stock Offering To Fund Development Of Type 1 Diabetes Therapy; No Terms Disclosed
SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced
03-18 04:03
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
